
Affimed Investor Relations Material
Latest events

Study Update
Affimed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Affimed N.V.
Access all reports
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company operates through two segments, Affimed Therapeutics, and Redoxa GmbH. It develops therapies based on its proprietary TandAb platform to unleash the innate power of the immune system by harnessing the functionality of natural killer cells and T-cells for the treatment of cancer.
The company has strategic partnerships with Genentech Inc.; Merck KGaA and Pfizer Inc.; Novartis Institutes for BioMedical Research, Inc.; Celgene Corporation; Bayer Pharma AG; MorphoSys AG; Incyte Corporation; Amgen Inc.; Hoffmann-La Roche ltd; Sanofi S.A.; and Bristol-Myers Squibb Company. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany
Key slides for Affimed N.V.


Study Update
Affimed N.V.


Corporate Presentation
Affimed N.V.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AFMD
Country
🇺🇸 United States